FDA Midyear 2026 Review

The first half of 2026 was anything but quiet at the U.S. Food and Drug Administration.

While many companies expected a slower regulatory environment amid broader federal government changes, FDA instead continued advancing significant initiatives affecting foods, beverages, dietary supplements, cosmetics, OTC drugs, and medical devices. The agency’s focus has increasingly shifted toward data-driven oversight, supply chain accountability, ingredient safety, and modernization of post-market regulatory frameworks.

A common theme has emerged across nearly every FDA-regulated industry: FDA is increasingly focused on systems, transparency, and risk-based oversight rather than simply identifying individual compliance violations. Companies that view compliance as a strategic business function rather than a regulatory obligation alone will be best positioned for the remainder of 2026 and beyond.

FDA’s Human Foods Program Has Entered Its Implementation Phase

The creation of FDA’s Human Foods Program (HFP) was one of the agency’s most significant structural reforms in decades. In 2026, the focus shifted from organizational design to execution.

In June, FDA released its updated Human Foods Program Guidance Agenda, identifying priorities that include food chemical safety, nutrition policy, microbiological food safety, use of the “Healthy” claim, caffeine labeling, and food facility registration updates.

For food and beverage companies, this signals a broader shift in regulatory priorities. Traditional manufacturing compliance remains important, but FDA appears increasingly interested in what companies are putting into products, how those products are marketed, and the scientific support underlying ingredient and labeling decisions.

What This Means for Industry

Food and beverage manufacturers should anticipate increased attention to:

• Ingredient safety determinations
• Nutrition and health-related claims
• Food chemical evaluations
• Labeling substantiation
• Product formulation decisions

The days when regulatory risk was driven primarily by GMP observations may be fading. Today’s risk calculus increasingly begins with the product itself.

Growing Pressure on the GRAS Framework

One of the most consequential developments for both food and dietary supplement companies is FDA’s continued focus on the Generally Recognized as Safe (GRAS) framework.

Industry observers have closely followed FDA’s efforts to revisit how GRAS determinations are made and whether greater agency involvement should be required for ingredients marketed under self-determined GRAS conclusions. Discussions surrounding a potential mandatory notification approach have continued gaining attention throughout 2026.

While formal rulemaking remains pending, the regulatory direction is becoming increasingly clear.

 

Strategic Takeaway

Companies introducing innovative ingredients should assume that scientific substantiation files may eventually receive a level of scrutiny comparable to materials submitted directly to FDA.

Robust GRAS dossiers are no longer merely defensive documents. They are becoming strategic assets.

Dietary Supplements Face Continued Demands for Transparency

Few sectors experienced more notable regulatory activity during the first half of 2026 than dietary supplements.

Congressional consideration of the Dietary Supplement Listing Act of 2026 would establish a mandatory FDA product listing framework for dietary supplements, potentially transforming FDA’s visibility into products marketed throughout the United States.

At the same time, FDA continues emphasizing dietary supplement CGMPs, recordkeeping requirements, and quality system documentation. Recent agency activity reinforces FDA’s expectation that companies maintain comprehensive records demonstrating identity, purity, strength, and composition controls.

Strategic Takeaway

The long-term trajectory is unmistakable:

• More product transparency
• More ingredient scrutiny
• Greater supply chain accountability
• Increased emphasis on quality systems

The supplement industry continues moving closer to regulatory models historically applied to other FDA-regulated product categories.

MoCRA Continues to Reshape the Cosmetics Industry

For cosmetics and personal care companies, 2026 has become the year of implementation.

Although the Modernization of Cosmetics Regulation Act (MoCRA) is no longer new, many companies are now confronting the practical realities of compliance involving facility registrations, product listings, adverse event reporting, mandatory recall authority and having recall plans in place, and safety substantiation obligations. Discussions throughout 2026 have consistently highlighted cosmetics regulation as a major area of FDA activity and industry concern.

Where FDA Risk Is Emerging

The greatest compliance exposure is often not found among large multinational cosmetic companies.

Instead, FDA scrutiny may disproportionately affect:

• Fast-growing direct-to-consumer brands
• Import-dependent businesses
• Contract manufacturing arrangements
• Companies without formal quality systems

As the industry continues adapting to MoCRA, safety documentation and operational controls are becoming competitive necessities.

FDA Is Intensifying Its Focus on Supply Chain Integrity

FDA’s recent communication regarding applications for Fiscal Year 2027 benefits under the Voluntary Qualified Importer Program (VQIP) underscores a broader regulatory trend: the agency is increasingly rewarding companies that can demonstrate effective supply chain oversight.

VQIP remains a cornerstone of FDA’s imported food safety strategy, encouraging importers to work with certified suppliers and implement robust controls throughout the supply chain.

Strategic Takeaway

Companies importing foods, supplements, cosmetic ingredients, OTC products, or device components should expect FDA inquiries to extend beyond the finished product.

The key question increasingly becomes:

Can you demonstrate control over your entire supply chain?

If the answer is uncertain, FDA may view that uncertainty as a compliance risk.

Medical Device Regulation Is Moving Deeper Into AI and Real-World Evidence

On the medical device side, FDA’s Center for Devices and Radiological Health (CDRH) continues focusing on artificial intelligence, real-world evidence (RWE), and adaptive technologies.

FDA’s Fiscal Year 2026 guidance priorities include initiatives related to:

• Use of real-world evidence
• AI-enabled medical devices
• Predetermined Change Control Plans (PCCPs)
• Modernized post-market oversight frameworks

 

Strategic Takeaway

Historically, the regulatory challenge was obtaining clearance.

Increasingly, the challenge is demonstrating how a device evolves safely after clearance.

Medical device companies should expect FDA’s post-market expectations to continue growing, particularly for products incorporating software and artificial intelligence technologies.

FDA Enforcement Is Becoming More Data-Driven

Perhaps the most important overarching development of 2026 is not a specific regulation at all.

It is FDA’s continued migration toward risk-based, data-driven oversight.

Industry commentary throughout the first half of 2026 has pointed to FDA’s increased use of integrated datasets, adverse event information, supply chain intelligence, product registrations, inspections, import data, and other sources to identify regulatory priorities and potential enforcement targets.

The New Compliance Reality

A decade ago, many companies prepared for FDA scrutiny when inspectors arrived.

Today, regulators often have significant information before stepping through the front door.

That information may come from:

• Adverse event reports
• Product listings
• Import records
• Online marketing claims
• Supplier information
• Consumer complaints

In many cases, FDA’s first impression of a company is increasingly formed through data.

Looking Ahead: What Companies Should Watch During the Second Half of 2026

Based on FDA’s stated priorities and emerging regulatory trends, companies should closely monitor:

• Human Foods Program implementation efforts.
• Potential developments relating to GRAS oversight.
• Dietary supplement transparency initiatives and listing proposals.
• Continued MoCRA implementation and cosmetics enforcement activity.
• Import compliance, FSVP, and VQIP developments.
• AI and real-world evidence guidance affecting medical devices.
• Expansion of risk-based enforcement approaches across FDA-regulated industries.

  

The Garg Law Perspective

The biggest FDA story of 2026 is not simply that regulations are changing.

It is that FDA increasingly expects companies to build compliance into their business infrastructure.

Whether you manufacture foods, beverages, dietary supplements, cosmetics, OTC drugs, or medical devices, regulatory success is becoming less about reacting to inspections and more about demonstrating control over ingredients, claims, supply chains, quality systems, and data before regulators ask the questions.

Companies that invest now in proactive regulatory strategy will be far better positioned than those waiting for the next warning letter, Form 483, import detention, or enforcement action.

 

For questions regarding FDA compliance, product development, labeling, MoCRA implementation, dietary supplement regulation, import compliance, medical device strategy or more, please contact info@garg-law.com.